Technology

Solventum Reports Second Quarter 2026 Financial Results

Published

3 months ago

August 5, 2026

Reported sales increased 2.2%; organic sales increased 9.5%Announces intent to separate its Health Information Systems business segmentIncreases full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow

EAGAN, Minn., Aug. 5, 2026 /PRNewswire/ — Solventum (NYSE: SOLV) today reported financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Highlights

Sales of $2.2 billion, increased 2.2% on a reported basis; an increase of 9.5% on an organic basisGAAP diluted earnings per share of $0.53; adjusted diluted earnings per share of $2.55, a 50.9% increaseOperating cash flow of $227 million; free cash flow of $144 million

“The Solventum team delivered another quarter of strong execution with results ahead of our expectations while continuing to advance our transformation,” said Bryan Hanson, chief executive officer of Solventum. “We remain on track to achieve our long-term objectives as we build a more focused, dedicated MedTech company, well-positioned to create long-term shareholder value.”

Second Quarter and First Six Months 2026 Financial Results

Three months ended June 30,

Six Months Ended June 30,

(Dollars in millions, except per share amounts)

2026

2025

Year-over-year
change

2026

2025

Year over year
change

Net sales

$ 2,209

$ 2,161

2.2 %

$ 4,216

$ 4,231

(0.4) %

Selling, general and administrative
expenses

$ 927

$ 772

20.1 %

$ 1,754

$ 1,541

13.8 %

Research and development
expenses

$ 178

$ 189

(5.8) %

$ 367

$ 381

(3.7) %

Operating income margin

8.2 %

9.9 %

(170) bps

6.2 %

8.7 %

(250) bps

Adjusted operating income margin1

28.4 %

21.9 %

650 bps

24.2 %

20.8 %

340 bps

Net income

$ 92

$ 90

2.2 %

$ 105

$ 227

(53.7) %

Diluted earnings per
share

$ 0.53

$ 0.51

3.9 %

$ 0.60

$ 1.30

(53.8) %

Adjusted diluted earnings per share1

$ 2.55

$ 1.69

50.9 %

$ 4.02

$ 3.03

32.7 %

Net cash provided by (used in)
operating activities

$ 227

$ 169

34.3 %

$ 38

$ 198

(80.8) %

Free cash flow1

$ 144

$ 59

144.1 %

$ (129)

$ (21)

(514.3) %

Represents non-GAAP financial measure; see the “Non-GAAP Financial Measures” section for applicable information.

Discussion of Second Quarter Results
All comparisons are to the prior year period unless otherwise noted

Organic sales growth of +9.5% in the quarter reflects strong performance across all reportable segments, primarily driven by volume and product mix and including the expected benefit of advance orders placed ahead of ERP cutovers.GAAP and adjusted gross margin both increased, driven by IEEPA tariff refund.GAAP selling, general and administrative expenses increased primarily due to higher costs associated with separation activities and net legal costs. Adjusted SG&A as a percent of sales was 26.0%, a decrease of 130 bps vs. prior year.GAAP operating income margin decreased, primarily driven by net legal costs, separation and restructuring costs. Adjusted operating income margin increased primarily due to a combination of IEEPA tariff refund and ERP-timing benefit.Operating cash flow for the quarter was $227 million and free cash flow was $144 million, ahead of expectations driven by timing of tax payments and insurance proceeds.

Other Business and Operational Highlights

Announced the intent to separate its Health Information Systems business segment as part of the portfolio optimization phase of its transformation strategy. The proposed separation is expected to strengthen Solventum’s focus as a dedicated MedTech company while enabling both businesses to pursue distinct growth and innovation priorities.The Solventum Foundation announced a $350,000 grant to America’s ToothFairy to expand access to oral health screenings, dental education and fluoride treatment for more than 100,000 children and caregivers in underserved communities over the next year.For the second year in a row, named a Best Company to Work For by U.S. News & World Report in the categories of ‘Health Care and Research’ and ‘Midwest.’

Segment and Total Company Net Sales for Second Quarter and First Six Months*

Three months ended June 30,

Increase/(Decrease)

(Dollars in millions)

2026

2025

Reported
growth

Currency
impact

Constant
currency2

Other3

Organic
growth

Advanced Wound Care

$ 537

$ 467

14.9 %

1.0 %

13.9 %

6.8 %

7.1 %

Infection Prevention and
Surgical Solutions

836

750

11.3

1.2

10.1

—

10.1

MedSurg

1,372

1,218

12.7

1.1

11.6

2.7

8.9

Dental Solutions

396

338

17.0

1.8

15.2

—

15.2

Health Information Systems

354

339

4.4

0.2

4.2

(1.2)

5.4

Total reportable segment
net sales

2,122

1,895

Purification and Filtration

—

189

All Other4

11.8

1.2

10.6

—

10.6

Total Company

$ 2,209

$ 2,161

2.2 %

1.0 %

1.2 %

(8.3) %

9.5 %

Six months ended June 30,

Increase/(Decrease)

(Dollars in millions)

2026

2025

Reported
growth

Currency
impact

Constant
currency2

Other3

Organic
growth

Advanced Wound Care

$ 1,034

$ 915

12.9 %

1.7 %

11.2 %

6.6 %

4.6 %

Infection Prevention and
Surgical Solutions

1,573

1,460

7.7

2.2

5.5

—

5.5

MedSurg

2,607

2,375

9.7

2.0

7.7

2.6

5.1

Dental Solutions

750

667

12.5

3.1

9.4

—

9.4

Health Information Systems

696

667

4.3

0.5

3.8

(1.3)

5.1

Total reportable segment
net sales

4,053

3,709

Purification and Filtration

—

369

All Other4

163

153

6.4

1.7

4.7

—

4.7

Total Company

$ 4,216

$ 4,231

(0.4) %

1.8 %

(2.2) %

(8.0) %

5.8 %

Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum. “NM” reflects results considered not meaningful due to sale of the Purification and Filtration business in September 2025.

Constant currency represents the change in net sales absent the impact on sales from foreign currency translation.

Other represents sales impact from acquisitions and divestitures measured separately for the first 12 months post-transaction. Acquisitions include sales from the December 2025 acquisition of Acera. Divestitures primarily represents lost sales from the Company’s Purification and Filtration business that was sold in September 2025.

All Other includes the Drinking Water business, which was previously reported within Purification and Filtration, and sales related to product supplied to 3M and other supply agreements related to legacy 3M business and assumed by the Company at Spin-Off.

Full-Year 2026 Guidance
Solventum is updating its full year 2026 guidance as follows:

Increased organic sales growth range to +2.5% to +3.0% (+3.5% to +4.0% excluding ~100 bps of SKU exit impact); from prior range of +2.0% to +3.0%Increased adjusted EPS range to $7.10 to $7.20; from the upper end of prior range of $6.40 to $6.60Increased free cash flow to be in the range of $200 million to $300 million; from prior estimate of ~$200M

Organic sales, adjusted diluted EPS and free cash flow amounts included in Solventum’s full-year guidance are non-GAAP financial measures. Solventum does not provide reconciliations of the forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items, such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items.

See the “Non-GAAP Financial Measures” section for explanations of our non-GAAP financial measures.

Earnings Conference Call
Solventum will host a conference call today, August 5, at 4:30 p.m. Eastern Time to discuss its second quarter financial results and fiscal year 2026 outlook. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers, using the conference ID 6342275.

A replay of the webcast, along with the earnings press release, slides highlighting the results and supplemental financial disclosures, will also be available at the same link on the Investor Relations section of the Company’s website.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934 that are subject to risks and uncertainties. Solventum intends the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in those sections. Forward-looking statements include all statements that are not historical facts, but instead represent only Solventum’s beliefs regarding future goals, plans and expectations about its prospects for the future and other events, many of which, by their nature, are inherently uncertain and outside of Solventum’s control. Forward-looking statements include those containing such words as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “guidance,” “intends,” “may,” “outlook,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “sees,” “should,” “targets,” “will,” “would,” or other words of similar meaning in connection with any discussion of future operating or financial performance, business plans or prospects, Solventum’s review of strategic alternatives for its health information systems business, or the potential benefits of any such strategic alternatives or transaction.

Among the factors that could cause actual results to differ materially from those described in our forward-looking statements are the following: (1) whether Solventum will be able to identify or develop any strategic alternatives for Solventum’s health information systems business; (2) Solventum’s ability to execute on material aspects of any strategic alternatives that are identified and pursued; (3) whether Solventum can actually achieve the potential benefits of any strategic alternatives; (4) the occurrence of any event, change or other circumstances that could give rise to the abandonment of the review of strategic alternatives or pursuit of a different structure or strategic alternative; (5) uncertainties as to the timing of the review of strategic alternatives; (6) the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises and other events beyond Solventum’s control; (7) operational execution risks; (8) damage to Solventum’s reputation or its brands; (9) risks from acquisitions, strategic alliances, divestitures and other strategic events; (10) Solventum’s business dealings involving third-party partners in various markets; (11) Solventum’s ability to access the capital and credit markets and changes in Solventum’s credit ratings; (12) exposure to interest rate and currency risks; (13) the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (14) reduction in customers’ research budgets or government funding; (15) the timing and market acceptance of Solventum’s new product and service offerings; (16) ongoing working relationships with certain key healthcare professionals; (17) changes in reimbursement practices of governments or private payers or other cost containment measures; (18) Solventum’s ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions and disruptive factors; (19) legal and regulatory proceedings and legal compliance risks (including third-party risks) with regards to antitrust, FCPA and other anti-bribery laws, environmental laws, anti-kickback and false claims laws, privacy laws, product liability claims, tax laws, and other laws and regulations in the United States and other countries in which Solventum operates; (20) potential liabilities related to per-and polyfluoroalkyl substances, collectively known as “PFAS”; (21) risks related to the highly regulated environment in which Solventum operates; (22) risks associated with product liability claims; (23) climate change and measures to address climate change; (24) security breaches and other disruptions to information technology infrastructure; (25) artificial intelligence risks; (26) Solventum’s failure to obtain, maintain, protect or effectively enforce its intellectual property rights; (27) pension and postretirement obligation liabilities; (28) Solventum’s separation from 3M and performance as a standalone company, including the tax-free nature of the spin and its ability to execute on its short- and long-range plans and capital allocation strategies; and (29) restructuring programs, and other risks and uncertainties described in Solventum’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

The above list is not exhaustive or necessarily set forth in the order of importance. Forward-looking statements are based on certain assumptions and expectations of future events and trends, and actual future results and trends may differ materially from historical results or those reflected in any such forward-looking statements depending on a variety of factors. A further description of these factors is located under “Cautionary Note Concerning Forward-Looking Statements” and “Risk Factors” in Solventum’s periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information, future events or otherwise, except as required by applicable law.

Non-GAAP Financial Measures
In addition to reporting financial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance and measuring cash available to invest in our business. The adjusted measures are not in accordance with, nor are they a substitute for, GAAP measures. These non-GAAP financial measures are supplemental measures of our performance and our liquidity that we believe help investors understand our underlying business performance and Solventum uses these measures as an indication of the strength of Solventum and its ability to generate cash.

Solventum calculates forward-looking non-GAAP financial measures, including organic sales growth, adjusted gross margin, adjusted operating income, adjusted operating income margin, adjusted effective tax rate, adjusted diluted earnings per share and free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. Solventum does not provide reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable GAAP measures as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items. The timing and amounts of these items are uncertain and could have a material impact on Solventum’s results in accordance with GAAP.

The Q2 2026 financial statements and financial information, including reconciliations of non-GAAP financial measures, are available on Solventum’s website: investors.solventum.com.

About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers’ toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients’ lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

Solventum Investor Contact:
investors@solventum.com

Solventum Media Contact:
news@solventum.com

Solventum Corporation
CONDENSED CONSOLIDATED STATEMENTS OF INCOME*
(Dollars in millions, except per-share data)
(Unaudited)

Three months ended June 30,

Six months ended June 30,

2026

2025

2026

2025

Net sales of product

$ 1,698

$ 1,668

$ 3,211

$ 3,265

Net sales of software and rentals

511

493

1,005

966

Total net sales

2,209

2,161

4,216

4,231

Cost of product

807

865

1,603

1,700

Cost of software and rentals

116

121

231

242

Gross profit

1,286

1,175

2,382

2,289

Selling, general and administrative expenses

927

772

1,754

1,541

Research and development expenses

178

189

367

381

Operating income

181

214

262

367

Interest expense, net

103

125

207

Other expense (income), net

Income before income taxes

108

103

123

141

Provision for (benefit from) income taxes

(86)

Net income

$ 92

$ 90

$ 105

$ 227

Earnings per share:

Basic earnings per share

$ 0.53

$ 0.52

$ 0.60

$ 1.31

Diluted earnings per share

0.53

0.51

0.60

1.30

Weighted-average number of shares outstanding:

Basic

172.7

174.1

173.5

173.9

Diluted

173.3

175.2

174.4

175.0

Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

Solventum Corporation
CONDENSED CONSOLIDATED BALANCE SHEETS*
(Dollars in millions, except per-share data)
(Unaudited)

June 30,

December 31,

2026

2025

Assets

Current assets

Cash and cash equivalents

$ 403

$ 878

Accounts receivable — net of allowances of $82 and $87

1,310

1,034

Due from related parties

122

150

Inventories

Finished goods

573

636

Work in process

218

201

Raw materials and supplies

249

229

Total inventories

1,040

1,066

Other current assets

865

731

Total current assets

3,741

3,859

Property, plant and equipment — net

1,565

1,326

Goodwill

5,626

5,704

Intangible assets — net

2,408

2,592

Other assets

904

814

Total assets

$ 14,243

$ 14,294

Liabilities

Current liabilities

Short-term borrowings and current portion of long-term debt

$ 506

$ —

Accounts payable

701

687

Due to related parties

331

435

Unearned revenue

596

621

Other current liabilities

1,528

1,393

Total current liabilities

3,663

3,136

Long-term debt

4,573

5,035

Pension and postretirement benefits

358

363

Deferred income taxes

157

164

Finance leases

207

—

Other liabilities

486

547

Total liabilities

$ 9,443

$ 9,245

Equity

Common stock, par value $0.01 per share, 750,000,000 shares authorized

$ 2

Shares – June 30, 2026: issued: 174,889,899; outstanding: 170,113,551

Shares – December 31, 2025: issued and outstanding: 173,490,864

Additional paid-in capital

3,919

3,876

Retained earnings

1,902

1,797

Treasury stock, at cost

(355)

—

Shares – June 30, 2026: 4,776,348

Shares – December 31, 2025: —

Accumulated other comprehensive income (loss)

(669)

(625)

Total equity

4,800

5,049

Total liabilities and equity

$ 14,243

$ 14,294

Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

Solventum Corporation
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS*
(Dollars in millions)
(Unaudited)

Six months ended June 30,

2026

2025

Cash flows from operating activities

Net income

$ 105

$ 227

Adjustments to reconcile net income to net cash provided by (used in) operating activities

Depreciation and amortization

268

251

Pension and postretirement benefit expense

Stock-based compensation expense

Deferred income taxes

(88)

(177)

Changes in assets and liabilities

Accounts receivable

(286)

(15)

Due from related parties

Inventories

(77)

Accounts payable

Due to related parties

(117)

(6)

Accrued compensation

(101)

(47)

All other operating activities — net

(100)

Net cash provided by operating activities

198

Cash flows from investing activities

Purchases of property, plant and equipment

(167)

(219)

Other — net

(5)

Net cash used in investing activities

(164)

(224)

Cash flows from financing activities

Repayment of debt

—

(200)

Proceeds from debt, net of issuance costs

—

Net transfers from (to) 3M

(30)

Purchases of treasury stock

(355)

—

Other — net

(44)

(19)

Net cash used in financing activities

(350)

(249)

Effect of exchange rate changes on cash and cash equivalents

Net increase (decrease) in cash and cash equivalents

(475)

(268)

Cash and cash equivalents at beginning of period

878

762

Less: Cash and cash equivalents within held for sale

—

(2)

Cash and cash equivalents at end of period

$ 403

$ 492

Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

Solventum Corporation
BUSINESS SEGMENTS – (CONTINUED)*
(Unaudited)

The Company’s operating activities are primarily managed through three segments: MedSurg, Dental Solutions, and Health Information Systems.

MedSurg provides:Advanced wound care products such as negative pressure wound therapy, advanced wound dressings, advanced skin care, and synthetic tissue matrices; andInfection prevention and surgical solutions products, such as I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies Original Equipment Manufacturer (“OEM”).Dental Solutions provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents that span the “life of the tooth,” including products designed for preventative dental care, direct and indirect restoration, and broad orthodontic needs.

Health Information Systems provides healthcare systems with software solutions — including computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms — that are designed to eliminate revenue cycle waste, create more time for patient care, and support value-based care.

Purification and Filtration consists of filters and membranes for biopharmaceutical and medical technologies, as well as microelectronics and food and beverage that were reported prior to the sale of the business in September 2025.

All Other primarily consists of our drinking water filtration business that was retained after the sale of the Purification and Filtration Business. All Other also includes sales and cost of sales related to our agreements to supply 3M and other supply agreements assumed by the Company at Spin-Off related to legacy 3M businesses, which were historically included within Corporate and Unallocated.

BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES*

Three months ended June 30, 2026

Three months ended June 30, 2025

(Dollars in millions)

Net sales

Operating
income

Operating
margin %

Net sales

Operating
income

Operating
margin %

Advanced Wound Care

$ 537

$ 467

Infection Prevention and Surgical
Solutions

836

750

MedSurg

1,372

$ 355

25.8 %

1,218

$ 210

17.3 %

Dental Solutions

396

131

33.0

338

28.5

Health Information Systems

354

145

41.0

339

120

35.5

Total reportable segment net
sales and operating income

2,122

631

1,895

426

Purification and Filtration

—

189

23.1

All Other

21.4

10.3

Amortization expense

(90)

(78)

Corporate and unallocated

(378)

(185)

Total Company

$ 2,209

$ 181

8.2 %

$ 2,161

$ 214

9.9 %

Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES*

Six Months Ended
June 30, 2026

Six Months Ended
June 30, 2025

(Dollars in millions)

Net Sales

Operating
Income

Operating
Margin %

Net Sales

Operating
Income

Operating
Margin %

Advanced Wound Care

$ 1,034

$ 915

Infection Prevention and Surgical
Solutions

1,573

1,460

MedSurg

2,607

$ 516

19.8 %

2,375

416

17.5 %

Dental Solutions

750

218

29.0

667

175

26.2

Health Information Systems

696

276

39.6

667

229

34.3

Total reportable segment net
sales and operating income

4,053

1,009

3,709

820

Purification and Filtration

—

369

19.2

All Other

163

18.6

153

12.7

Amortization Expense

(181)

(159)

Corporate and Unallocated

(597)

(384)

Total Company

$ 4,216

$ 262

6.2 %

$ 4,231

367

8.7 %

Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

Solventum Corporation
SUPPLEMENTAL FINANCIAL INFORMATION
NON-GAAP MEASURES
(Unaudited)

In addition to reporting financial results in accordance with U.S. GAAP, the Company uses non-GAAP financial measures to supplement the financial measures prepared in accordance with U.S. GAAP. These include (1) adjusted gross margin, adjusted operating income and adjusted operating income margin, (2) adjusted diluted earnings per share, and (3) free cash flow. Management believes that these non-GAAP financial measures are useful in evaluating current performance and focusing management on our underlying operational results.

There are limitations to the use of the non-GAAP financial measures presented in this information statement. These non-GAAP financial measures are not prepared in accordance with U.S. GAAP nor do they have any standardized meaning under U.S. GAAP. In addition, other companies may use similarly titled non-GAAP financial measures that are calculated differently from the way we calculate such measures. Accordingly, our non-GAAP financial measures may not be comparable to such similarly titled non-GAAP financial measures used by other companies. Management cautions you not to place undue reliance on these non-GAAP financial measures, but instead to consider them with the most directly comparable U.S. GAAP measure. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation. These non-GAAP financial measures should be considered supplements to, not substitutes for, or superior to, the corresponding financial measures calculated in accordance with U.S. GAAP.

The tables below reconcile our non-GAAP financial measures to the nearest financial measure that is in accordance with U.S. GAAP for the periods presented.

Adjusted Gross Margin, Adjusted Operating Income, Adjusted Operating Income Margin and Adjusted Earnings Per Share (Non-GAAP measures)

Adjusted gross margin, adjusted operating income and adjusted operating income margin are not defined under U.S. GAAP. Therefore, they should not be considered a substitute for earnings data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. Solventum defines adjusted gross margin as gross margin excluding the effects of restructuring costs, Spin-Off and separation-related costs, separation-related impacts due to the sale of the Purification and Filtration business, and acquisition-related costs. Solventum defines adjusted operating income as operating income excluding the effects of amortization, restructuring costs, Spin-Off and separation-related costs, certain litigation-related costs, separation-related impacts due to the sale of the Purification and Filtration business, acquisition-related costs and costs related to the planned separation of the Health Information Systems business. Adjusted operating income margin is adjusted operating income divided by the U.S GAAP measure total net sales for the same period. The Company believes adjusted gross margin, adjusted operating income and adjusted operating income margin provide investors with visibility into the Company’s unleveraged, pre-tax operating results and reflects underlying financial performance. However, adjusted gross margin and adjusted operating income should not be construed as inferring that the Company’s future results will be unaffected by the items for which the measure adjusts.

Adjusted diluted earnings per share is not defined under U.S. GAAP. Therefore, it should not be considered a substitute for earnings data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. Solventum defines adjusted diluted earnings per share as net income excluding the after-tax effects of amortization, restructuring costs, Spin-Off and separation-related costs, certain litigation-related costs, separation-related impacts due to the sale of the Purification and Filtration business, acquisition-related costs and costs related to the planned separation of the Health Information Systems business. The Company believes adjusted earnings per share provides investors with improved comparability of underlying operating results and a further understanding and additional transparency regarding how the Company evaluates the business. However, adjusted earnings per share should not be construed as inferring that the Company’s future results will be unaffected by the items for which the measure adjusts.

Solventum Corporation
SUPPLEMENTAL FINANCIAL INFORMATION
NON-GAAP MEASURES – (CONTINUED)*
(Unaudited)

Three months ended June 30, 2026

(Dollars in millions, except per
share amounts)

Net sales

Cost of
sales5

Gross
margin %

Operating
expenses6

Operating
income

Operating
income
margin %

Non-operating
expense
(income), net7

Income
before
income
taxes

Net income
attributable
to Solventum

Diluted
EPS

Effective
tax rate

GAAP

$ 2,209

$ 923

58.2 %

$ 1,105

$ 181

8.2 %

$ 73

$ 108

$ 92

$ 0.53

14.4 %

Non-GAAP adjustments:

Amortization of acquisition-
related intangible assets

—

(90)

4.1

—

0.44

Restructuring costs (a)

—

(9)

0.4

(33)

1.9

—

0.18

3M spin-off and separation-
related costs (b)

—

(33)

1.5

(112)

145

6.6

—

145

114

0.65

Certain litigation-related
costs (c)

—

(157)

157

7.1

—

157

119

0.69

Purification and Filtration
separation-related (d)

—

(8)

(0.4)

—

(8)

(6)

(0.04)

Acquisition-related costs(e)

—

(15)

0.7

—

0.07

Planned separation of
Health Information Systems-
related (f)

—

(6)

0.3

—

0.03

Non-GAAP

$ 2,209

$ 881

60.1 %

$ 701

$ 627

28.4 %

$ 73

$ 554

$ 442

$ 2.55

20.2 %

Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

Three months ended June 30, 2025

(Dollars in millions, except per
share amounts)

Net sales

Cost of
sales5

Gross
margin %

Operating
expenses6

Operating
income

Operating
income
margin %

Non-operating
expense
(income), net7

Income
before
income
taxes

Net income
attributable
to Solventum

Diluted
EPS

Effective
tax rate

GAAP

$ 2,161

$ 986

54.4 %

$ 961

$ 214

9.9 %

$ 111

$ 103

$ 90

$ 0.51

12.5 %

Non-GAAP adjustments:

Amortization of acquisition-
related intangible assets

—

(78)

3.6

—

0.38

Restructuring costs (a)

—

(1)

0.1

(7)

0.5

—

0.03

3M spin-off and separation-
related costs (b)

—

(33)

1.5

(117)

150

6.9

—

150

115

0.66

Certain litigation-related
costs (c)

—

(8)

0.4

—

0.03

Purification and Filtration
separation-related (d)

—

(15)

0.7

—

0.07

Non-GAAP

$ 2,161

$ 952

56.0 %

$ 736

$ 474

21.9 %

$ 111

$ 362

$ 296

$ 1.69

18.3 %

Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

(a)

2026 restructuring costs primarily related to the Company’s Transform for the Future program. Includes employee termination costs of $11 million and other costs of $31 million, which includes third-party consulting, asset write-downs and compensation for employees dedicated to the program. 2025 restructuring costs primarily relate to the Company’s Solventum Way program. Includes employee termination costs of $9 million and other costs of $(1) million.

(b)

Consists of costs specifically incurred in connection with the Company’s separation from 3M.

(c)

Consists of charges and recoveries related to certain litigation matters.

(d)

2026 activity consists of the profit mark-up from transition support services. 2025 activity consists of costs related to and tax impacts from the separation of the Company’s Purification and Filtration business, including legal, finance and tax advisory.

(e)

Integration costs related to the acquisition of Acera Surgical, including amortization of inventory step-up.

(f)

Costs related to the planned separation of the Company’s Health Information Systems business.

Cost of sales is the combination of cost of product and cost of software and rentals line items from the Condensed Consolidated Statements of Income and represents the total Company’s cost of sales.

Operating expenses is the combination of selling, general and administrative expenses and research and development expenses from the Condensed Consolidated Statements of Income and represents the total Company’s other operating expenses.

Non-operating expense (income), net is the combination of interest expense, net, and other expense (income), net line items from the Condensed Consolidated Statements of Income and represents the total Company’s non-operating expense.

Solventum Corporation
SUPPLEMENTAL FINANCIAL INFORMATION
NON-GAAP MEASURES – (CONTINUED)*
(Unaudited)

Six months ended June 30, 2026

(Dollars in millions, except per share amounts)

Net sales

Cost
of Sales5

Gross
Margin %

Operating
Expenses6

Operating
Income

Operating
Income
Margin %

Non-Operating
Expense
(Income), net7

Income
Before
Income
Taxes

Net Income
Attributable to
Solventum

Diluted
EPS

Effective
Tax Rate

GAAP

$ 4,216

$ 1,833

56.5 %

$ 2,121

$ 262

6.2 %

$ 138

$ 123

$ 105

$ 0.60

15.0 %

Non-GAAP Adjustments:

Amortization of acquisition-
related intangible assets

—

(181)

181

4.3

—

181

152

0.87

Restructuring costs (a)

—

(10)

0.2

(73)

2.0

—

0.36

3M spin-off and separation-
related costs (b)

—

(64)

1.5

(244)

308

7.3

—

308

241

1.38

Certain litigation-related
costs (c)

—

(171)

171

4.0

—

171

129

0.74

Purification and Filtration
separation-related (d)

—

(12)

(0.3)

—

(12)

(9)

(0.05)

Acquisition-related costs(e)

—

(4)

0.1

(17)

0.5

—

0.09

Planned separation of
Health Information Systems-related (f)

—

(6)

0.1

—

0.02

Non-GAAP

$ 4,216

$ 1,755

58.4 %

$ 1,441

$ 1,019

24.2 %

$ 138

$ 881

$ 702

$ 4.02

20.3 %

Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

Six months ended June 30, 2025

(Dollars in millions, except per share amounts)

Net sales

Cost of
Sales5

Gross
Margin %

Operating
Expenses6

Operating
Income

Operating
Income
Margin %

Non-Operating
Expense
(Income), net7

Income
Before
Income
Taxes

Net Income
Attributable to
Solventum

Diluted
EPS

Effective
Tax Rate

GAAP

$ 4,231

$ 1,942

54.1 %

$ 1,922

$ 367

8.7 %

$ 226

$ 141

$ 227

$ 1.30

(61.0) %

Non-GAAP Adjustments:

Amortization of acquisition-
related intangible assets

—

(159)

159

3.7

—

159

135

0.77

Restructuring costs (a)

—

(11)

0.3

(15)

0.6

—

0.11

3M spin-off and separation-
related costs (b)

—

(60)

1.4

(210)

272

6.4

—

272

209

1.20

Certain litigation-related
costs (c)

—

(27)

0.6

—

0.11

Purification and Filtration
separation-related (d)

—

(31)

0.7

—

(80)

(0.46)

Non-GAAP

$ 4,231

$ 1,871

55.8 %

$ 1,480

$ 881

20.8 %

$ 226

$ 655

$ 530

$ 3.03

19.0 %

Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

(a)

2026 restructuring costs primarily relate to the Company’s Transform for the Future program. Includes employee termination costs of $16 million and other costs of $66 million, which includes third-party consulting, asset write-downs and compensation for employees dedicated to the program. 2025 restructuring costs primarily related to the Company’s Solventum Way program. Includes employee termination costs of $23 million and other costs of $3 million.

(b)

Consists of costs specifically incurred in connection with the Company’s separation from 3M.

(c)

Consists of charges and recoveries related to certain litigation matters.

(d)

(e)

Integration costs related to the acquisition of Acera Surgical, including amortization of inventory step-up.

(f)

Costs related to the planned separation of the Company’s Health Information Systems business.

Cost of sales is the combination of cost of product and cost of software and rentals line items from the Consolidated Statements of Income and represents the total Company’s cost of sales.

Operating expenses is the combination of selling, general and administrative expenses and research and development expenses from the Consolidated Statements of Income and represents the total Company’s other operating expenses.

Non-operating expense (income), net is the combination of interest expense, net, loss on debt extinguishment, net, and other expense (income), net line items from the Consolidated Statements of Income and represents the total Company’s non-operating expense.

Solventum Corporation
SUPPLEMENTAL FINANCIAL INFORMATION
NON-GAAP MEASURES – (CONTINUED)*
(Unaudited)

Free Cash Flow (non-GAAP measure):

Free cash flow is not defined under U.S. GAAP. Therefore, it should not be considered a substitute for income or cash flow data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. The Company defines free cash flow as net cash provided by (used in) operating activities less purchases of property, plant and equipment. It should not be inferred that the entire free cash flow amount is available for discretionary expenditures. The Company believes free cash flow is meaningful to investors as it is a useful measure of liquidity and the Company uses this measure as an indication of the strength of the Company and its ability to generate cash. Free cash flow varies across quarters throughout the year. Below find a recap of free cash flow.

(Dollars in millions)

Three months ended June 30,

Six months ended June 30,

Major GAAP cash flow categories

2026

2025

2026

2025

Net cash provided by operating activities

227

169

198

Net cash used in investing activities

(87)

(110)

(164)

(224)

Net cash used in financing activities

(300)

(110)

(350)

(249)

Free cash flow (non-GAAP measure)

Net cash provided by operating activities

227

169

198

Purchases of property, plant and equipment

(83)

(110)

(167)

(219)

Free cash flow

144

(129)

(21)

Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

View original content to download multimedia:https://www.prnewswire.com/news-releases/solventum-reports-second-quarter-2026-financial-results-302844198.html

SOURCE Solventum

Technology

Solidion Technology (NASDAQ: STI) Reports Third Quarter Financial Results, Highlighting Strong Cash Balance, Reduction in Liabilities and Positive EPS

Published

15 minutes ago

November 9, 2026

Company Maintains Strong Cash Position of $26.2 Million, Reduces Total Liabilities by Approximately 40%, and Reports Positive Earnings per Share (EPS) of $0.02

DALLAS, Nov. 9, 2026 /PRNewswire/ — Solidion Technology, Inc. (NASDAQ: STI) (“Solidion Technology” or “the Company”), an advanced battery technology provider, today reported its Third Quarter 2026 Financial and Operating Results. The condensed consolidated financial statements of Solidion Technology and additional information can be found in Solidion Technology’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission on November 9, 2026 (the “Form 10-Q”). This earnings release should be read together with the information contained in the Form 10-Q.

Solidion Technology maintained a healthy cash balance of approximately $26.2 million, reduced total liabilities by approximately 40% compared to year-end 2025, and reported positive net income for the quarter.

Third Quarter 2026 Financial and Corporate Highlights

Strong Liquidity: Maintained cash and cash equivalents of $26.2 million as of September 30, 2026, compared to $27.7 million at June 30, 2026.Positive Working Capital: Working capital of $19.6 million as of September 30, 2026, compared to a deficit of $11.2 million at December 31, 2025.Reduced Liabilities: Total liabilities declined approximately 40% to $7.5 million, compared to $12.0 million at December 31, 2025.Positive Net Income: Reported quarterly net income of approximately $244,000, compared to a net loss of $4.1 million in the prior-year period.Strengthened Stockholders’ Equity: Stockholders’ equity reached $23.8 million, compared to a deficit of $7.2 million at year-end 2025.Financial Flexibility: The Company believes its capital position supports continued investment in its technology portfolio and evaluation of strategic acquisition opportunities.Board Governance: On August 31, 2026, the Company expanded its Board of Directors with the appointment of three independent directors, Mark Schwartz, Kimi L. Ellen and Dante W. Robinson.Share Repurchase Program: On September 13, 2026, the Board of Directors authorized the repurchase of up to $1.0 million of the Company’s common stock.

TABLE 1: QUARTERLY FINANCIAL PERFORMANCE

Metric

Q3 2026

Q3 2025

Revenue

$41,638

$9,350

Cost of revenue

$120,000

$4,321

Selling, general and administrative, Research and Development

$2,240,915

$1,747,929

Total other income (expense)

$2,563,700

$(2,349,245)

Basic earnings (loss) per share

$0.02

$(1.33)

“During the third quarter, we continued strengthening Solidion Technology’s financial foundation while positioning the Company for its next phase of growth,” said Jaymes Winters, Chief Executive Officer of Solidion Technology. “We remain disciplined and opportunistic in our approach to acquisitions. Our healthy cash position and improved balance sheet provide us with the flexibility to continue to pursue opportunities that complement our existing technology and manufacturing capabilities.”

“We believe our strategy positions Solidion Technology to capitalize on opportunities across the energy storage industry, while maintaining our commitment to long-term shareholder value.”

Business Highlights

Technology and Commercialization

PEAK Series UPS for AI Data Centers: Solidion has developed its PEAK Series uninterruptible power supply system using its 5500 silicon-carbon anode cell. Based on Company testing, the system is designed to reduce UPS footprint by up to 30%, while the cell is designed to last up to three times longer than conventional backup battery systems.High-Power Battery Cells: Solidion has developed its high-energy 5.5Ah 21700 cylindrical cell, with an energy density of 305 Wh/kg and continuous charge/discharge capability exceeding 2C.Government Research Programs: Solidion is conducting research under two U.S. Department of Energy grants, both conducted jointly with Oak Ridge National Laboratory, the Company’s partner on its 2025 R&D 100 Award. The Company is also performing research under a firm-fixed-price U.S. Army STTR contract to develop a flexible, fiber-based rechargeable battery system.

Strategic Priorities

For the remainder of 2026 and into 2027, Solidion Technology intends to remain an opportunistic and disciplined acquirer of revenue-generating assets and businesses in the battery storage sector that amplify its existing technology and IP portfolio while simultaneously advancing its commercialization initiatives and strengthening its manufacturing and commercial capabilities.

About Solidion Technology, Inc.

Solidion Technology, Inc. (NASDAQ: STI) is an advanced battery technology company headquartered in Dallas, Texas, with R&D and manufacturing operations in Dayton, Ohio. Solidion develops silicon-rich anodes, solid-state batteries, and fire-retardant electrolytes designed to deliver higher energy density, improved safety, and lower cost for the electric vehicle, energy storage, consumer electronics, aerospace and defense, and AI data center markets, including next-generation backup power for data center operators. The Company is backed by a global portfolio of over 385 patents covering innovations such as high-capacity, silane gas-free, and graphene-enabled silicon anodes, biomass-based graphite, and advanced lithium-sulfur and lithium-metal technologies. Solidion also pursues a disciplined acquisition strategy focused on opportunities that complement its platform and create long-term shareholder value.

For more information, please visit www.ir.solidiontech.com or contact Investor Relations.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Solidion Technology Inc., (NASDAQ: STI) (the “Company,” “Solidion,” “we,” “our” or “us”) desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The statements contained in this press release that are not purely historical are forward-looking statements. Without limitation, any statements preceded or followed by or that include the words “forecasts” “believe,” “may,” “will,” “would,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “position,” “is likely,” “expect” and similar expressions or the negative thereof, as they relate to us, are intended to identify forward-looking statements. Forward-looking statements in this press release may include, for example, statements about our financial and business performance and statements about our business, expansion plans and opportunities. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, assumptions and other factors, some of which are beyond our control, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the inability of our batteries to perform as expected, including design or manufacturing defects; competition in the evolving battery cell market and the selection of other battery cell technologies by OEMs; the need for additional safety testing of our battery technology before it can be installed in electric vehicles; reliance on complex production equipment, and operational and cost uncertainty in production; the performance of licensed technologies that have not been commercialized, or have only been commercialized to a limited extent; raw material and component price increases, supply constraints, and our ability to control costs and achieve cost advantages at scale; the pace of consumer adoption of electric vehicles; the unavailability of government incentives and subsidies; our ability to attract customers and to accurately forecast supply, demand and manufacturing requirements; our ability to attract and retain key employees and qualified personnel; our limited operating history and untested business model; our history of losses; our ability to obtain additional capital on commercially reasonable terms, or at all; our ability to manage growth and build our brand; the accuracy of assumptions and estimates behind our technical and production timelines and our financial statements; material weaknesses in our internal control over financial reporting; product liability claims, litigation, regulatory actions and government investigations; substantial and changing regulations; cybersecurity incidents, security breaches, and data privacy compliance; tariffs and trade tensions, including a potential global trade war; and other risks detailed in our other Securities and Exchange Commission filings, particularly in the section titled “Risk Factors” contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by law.

Please follow us on:

LinkedIn: https://www.linkedin.com/company/solidion-tech

X: https://x.com/solidiontech

View original content to download multimedia:https://www.prnewswire.com/news-releases/solidion-technology-nasdaq-sti-reports-third-quarter-financial-results-highlighting-strong-cash-balance-reduction-in-liabilities-and-positive-eps-302933931.html

SOURCE Solidion Technology, Inc.

Technology

Solidion Technology (NASDAQ: STI) Reports Third Quarter Financial Results, Highlighting Strong Cash Balance, Reduction in Liabilities and Positive EPS

Published

15 minutes ago

November 9, 2026

Company Maintains Strong Cash Position of $26.2 Million, Reduces Total Liabilities by Approximately 40%, and Reports Positive Earnings per Share (EPS) of $0.02

Third Quarter 2026 Financial and Corporate Highlights

TABLE 1: QUARTERLY FINANCIAL PERFORMANCE

Metric

Q3 2026

Q3 2025

Revenue

$41,638

$9,350

Cost of revenue

$120,000

$4,321

Selling, general and administrative, Research and Development

$2,240,915

$1,747,929

Total other income (expense)

$2,563,700

$(2,349,245)

Basic earnings (loss) per share

$0.02

$(1.33)

“We believe our strategy positions Solidion Technology to capitalize on opportunities across the energy storage industry, while maintaining our commitment to long-term shareholder value.”

Business Highlights

Technology and Commercialization

Strategic Priorities

About Solidion Technology, Inc.

For more information, please visit www.ir.solidiontech.com or contact Investor Relations.

Forward-Looking Statements

Please follow us on:

LinkedIn: https://www.linkedin.com/company/solidion-tech

X: https://x.com/solidiontech

SOURCE Solidion Technology, Inc.

Technology

FXT Named Most Innovative Broker at the 2026 Finance Magnates Awards

Published

15 minutes ago

November 9, 2026

Trader-first innovation recognised across FXT’s all-in-one trading ecosystem.

SYDNEY, Nov. 10, 2026 /PRNewswire/ — FXT has been named Most Innovative Broker 2026 in the global brokerage category at the Finance Magnates Awards, announced on 6 November in Limassol, Cyprus.

For FXT, the award marks more than technology. It celebrates a philosophy pursued since 2014: relentless innovation, Total Quality Management and the belief that every advancement should give traders more clarity, control and choice when markets move.

That philosophy shapes FXT’s all-in-one trading ecosystem, connecting multi-asset CFD trading, MetaTrader platforms, FXT WebTrader, the FXT App trading experience and account tools. Rather than forcing traders to piece together disconnected services, FXT is building around their decisions and workflows.

At the centre is FXT AI, an in-house, multi-agent trading co-pilot integrated into the FXT client environment, not a generic AI plug-in. Its Market Reader, Trade Mentor and Risk Monitor are designed to bring market context, trading behaviour and open-position exposure into clearer view. FXT AI supports decision-making; traders remain in control.

FXT Social Trading extends that approach, connecting Strategy Providers and Followers within a dedicated copy-trading ecosystem. Together, these capabilities reflect innovation shaped around real trading needs, not technology for technology’s sake.

“This is a proud moment for everyone at FXT. Our ambition has always been to put traders at the centre of the technology we build. Innovation and precision are not separate promises; they are the standards we work to every day,” said CEO Adam Phillips.

The award provides momentum to FXT’s brand belief: In Control. When It Gets Real. Because when markets become unpredictable, traders deserve tools built for the moments that matter.

About FXT
FXT is a global multi-asset forex and CFD broker built for traders who want greater clarity, control and choice when markets move. Since 2014, more than 100,000 traders worldwide have used FXT to access 200+ instruments across forex, indices, commodities and share CFDs. FXT supports trading through MT4, MT5, FXT WebTrader and the FXT Mobile App, with FXT AI built into the account experience.

FXT is a registered business name of Gleneagle Securities Pty Ltd, licensed by the Vanuatu Financial Services Commission under licence number 40256.

CFDs are leveraged products and carry a high risk of loss. Product availability, trading conditions and protections vary by jurisdiction and account type.

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/fxt-named-most-innovative-broker-at-the-2026-finance-magnates-awards-302933943.html

Technology3 days ago

Diamond Foundry Announces First-Ever D200mm Single-Crystal Diamond

Coin Market4 days ago

Crypto exchanges tout cold storage ratios after Binance attack

Near Videos5 days ago

Where AI money lands in crypto

Technology4 days ago

2026 World Internet Conference Wuzhen Summit Opens

Technology4 days ago

OpenAssets and Digital Asset Partner to Modernize Capital Markets Infrastructure

Technology5 days ago

Finshape launches Agentic DBOS: agentic AI already supporting digital banking projects

Technology4 days ago

ASTRI Establishes Advisory Board for Smart Mobility Technology Alliance

Technology5 days ago

When Trade Reaches New Markets, Money Has to Keep Pace

Nativo Ventures

Solventum Reports Second Quarter 2026 Financial Results

Technology

Solventum Reports Second Quarter 2026 Financial Results

Technology

Solidion Technology (NASDAQ: STI) Reports Third Quarter Financial Results, Highlighting Strong Cash Balance, Reduction in Liabilities and Positive EPS

Technology

Solidion Technology (NASDAQ: STI) Reports Third Quarter Financial Results, Highlighting Strong Cash Balance, Reduction in Liabilities and Positive EPS

Technology

FXT Named Most Innovative Broker at the 2026 Finance Magnates Awards

Solidion Technology (NASDAQ: STI) Reports Third Quarter Financial Results, Highlighting Strong Cash Balance, Reduction in Liabilities and Positive EPS

Solidion Technology (NASDAQ: STI) Reports Third Quarter Financial Results, Highlighting Strong Cash Balance, Reduction in Liabilities and Positive EPS

FXT Named Most Innovative Broker at the 2026 Finance Magnates Awards

Send Rakhi to UK swiftly with UK Gifts Portal

Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network

Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market

Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs

Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network

NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap

Trending

Nativo Ventures

Solventum Reports Second Quarter 2026 Financial Results

You may like

Technology

Solidion Technology (NASDAQ: STI) Reports Third Quarter Financial Results, Highlighting Strong Cash Balance, Reduction in Liabilities and Positive EPS

Technology

Solidion Technology (NASDAQ: STI) Reports Third Quarter Financial Results, Highlighting Strong Cash Balance, Reduction in Liabilities and Positive EPS

Technology

FXT Named Most Innovative Broker at the 2026 Finance Magnates Awards

Solidion Technology (NASDAQ: STI) Reports Third Quarter Financial Results, Highlighting Strong Cash Balance, Reduction in Liabilities and Positive EPS

Solidion Technology (NASDAQ: STI) Reports Third Quarter Financial Results, Highlighting Strong Cash Balance, Reduction in Liabilities and Positive EPS

FXT Named Most Innovative Broker at the 2026 Finance Magnates Awards

Send Rakhi to UK swiftly with UK Gifts Portal

Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network

Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market

Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs

Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network

NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap

Trending